Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Septic Arthritis in Sickle Cell Anemia
source: Family Practice Notebook
year: 2018
summary/abstract:Septic Arthritis in Sickle Cell Anemia:
II. Causes
Staphylococcus aureus (most common cause)
Streptococcus Pneumoniae
Salmonella
III. Labs
Synovial Fluid (obtain in all suspected cases)
1. Normal Synovial Fluid cell count in >50% of Septic Arthritis cases
2. Gram Stain Test Sensitivity is only 50% (high False Negative Rate)
3. Synovial Fluid is the gold standard for diagnosis
IV. Management
A. Obtain Synovial Fluid culture and start empiric antibiotics
B. Total antibiotic course: 6 weeks
C. Initial empiric management
1. Cephaloporin sensitive
a. Ceftriaxone 50-75 mg/kg up to 2 g/dose OR
b. Ceftriaxone 75-100 mg/kg in high S. Pneumoniae resistance regions
2. Cephalosporin resistance
a. Clindamycin 10-15 mg/kg/dose (preferred) OR
b. Vancomycin 15 mg/kg/dose (if systemic Sepsis or Clindamycin reactions)
+myBinderRelated Content
-
Sickle Cell Disease and Cold Weather: Dos and Don’tsIn the United States today, one of every...
-
Sickle cell disease is associated with higher mortality among patients hospitalized with ischemic bowel diseaseBackground: Sickle cell disease (SCD) i...
-
APS Scientific Meeting 2019The American Pain Society will hold its ...
-
Sickle Cell Anemia Treatment & ManagementThe National Institutes of Health advise...
-
Black Americans With Sickle Cell Trait At Increased Risk Of Kidney DiseaseAfrican Americans with sickle cell trait...
-
Multidisciplinary Care Team Greatly Reduces Risk in Pregnant SCD Patients in Low-income CountriesAccording to a study published in the Am...
-
When Cracking Down On Opioids Means Tougher Access For Sickle Cell PatientsMany people with sickle cell disease wil...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.